Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda

Abstract

BackgroundUgandan national guidelines recommend initiation of combination antiretroviral therapy (cART) at CD4+ T cell (CD4) count below 350 cell/μl, but the implementation of this is limited due to availability of medication. However, cART initiation at higher CD4 count increases survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250–350 cell/μl (early) versus <250 cell/μl (delayed).MethodsLife expectancy of cART-treated patients, conditional on baseline CD4 count, was modeled based on published literature. First-line cART costs $192 annually, with an additional $113 for patient monitoring. Delaying initiation of cART until the CD4 count falls below 250 cells/μl would incur the cost of the bi-annual CD4 count tests and routine maintenance care at $85 annually. We compared lifetime treatment costs and disability adjusted life-expectancy between early vs. delayed cART for ten baseline CD4 count ranges from 250-350 cell/μl. All costs and benefits were discounted at 3% annually.ResultsTreatment delay varied from 6–18 months. Early cART initiation increased life expectancy from 1.5-3.5 years and averted 1.33–3.10 disability adjusted life years (DALY’s) per patient. Lifetime treatment costs were $4,300–$5,248 for early initiation and $3,940–$4,435 for delayed initiation. The cost/DALY averted of the early versus delayed start ranged from $260–$270.ConclusionsIn HIV-positive patients presenting with CD4 count between 250-350 cells/μl, immediate initiation of cART is a highly cost-effective strategy using the recommended one-time per capita GDP threshold of $490 reported for Uganda. This would constitute an efficient use of scarce health care funds.

Research priorities to inform “Treat All” policy implementation for people living with HIV in sub‐Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA)

“… Context: The use of mathematical modelling techniques, coupled with detailed, individual‐level observational data, can inform Treat All policy questions, including the efficiency, prioritization and affordability of HIV‐related interventions . A strong modelling literature confirms that earlier ART initiation reduces morbidity and mortality, is cost‐effective compared to deferred ART initiation , and prevents new HIV infections , which may reduce population‐level economic costs . However, additional work is needed to develop and validate mathematical models that better reflect local clinical context (e.g.…”

Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Uganda

“…Prenatal misoprostol distribution appears to be a good buy when compared to other interventions which are currently implemented in Uganda, such as short course amphotericin (7 days) plus high dose fluconazole (1200mg/day) versus high dose fluconazole monotherapy ($15.11/QALY gained) for Cryptococcal meningitis in HIV patients [ 61 ], and early versus delayed initiation of HAART ($460/DALY averted) [ 62 ]. It compares favorably with other interventions targeting maternal health e.g., universal access to contraceptives, which both save lives and save costs [ 58 ].…”

Financing structural interventions

“…This is primarily derived from a human capital approach, whereby a year of life is valued as an individual's economic productivity [49]. Although there are a range of other approaches [45], the WHO benchmark was taken as it is commonly used in economic evaluations of HIV interventions [29,50,51].…”